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Summary
Objective: To study the relations between knee joint abnormalities, reflected by bone scintigraphy and serum
concentrations of cartilage oligomeric matrix protein (COMP) and bone sialoprotein (BSP).
Design: In a group of 38 individuals aged 37–54 years with chronic knee pain for more than four years, both knees
were investigated with bone scan. The bone scans were graded for the extent of abnormalities. Radiographs of both
knees were graded for tibiofemoral and patellofemoral osteoarthritis (OA). Serum levels of COMP and BSP were
measured by immunoassays.
Results: Bone scan abnormalities were detected in 26/38 individuals and radiographic OA in 23/38 individuals. The
serum concentrations of COMP and BSP were significantly higher in the individuals with bone scan abnormalities
(P = 0.02 and P = 0.004, respectively). In addition, the serum levels of COMP correlated positively with the extent of
bone scan abnormalities (N = 38), r = 0.56, P = 0.002. Serum BSP did not correlate to the extent of scan abnormalities.
Conclusions: In individuals with knee pain, serum levels of COMP and BSP differ between those with or without
bone scan abnormalities in the knee joints. This suggests that measurements of the serum levels of these markers have
potential as means for evaluation of tissue changes in individuals with long standing knee pain in relation to early
stages of OA.
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Introduction
Osteoarthritis (OA) of the peripheral joints is
a common disease in all populations studied
[1, 2]. The disease is currently diagnosed by
clinical and/or radiographic criteria which only
allow detection of fairly advanced stages of the
disease process [3]. The lack of means for
establishing an early diagnosis, has as yet
precluded studies of early changes in the tissue
turnover in cartilage and bone in patients at a
stage when changes crucial for subsequent
development of irreversible joint damage occur.
It appears that an important feature of the
process is a disturbance of the normal balance
between synthesis and degradation of matrix
macromolecules in the articular cartilage and
subchondral bone. Reliable and sensitive means
for monitoring such changes would facilitate
clinical investigations of key events in the
pathophysiology of OA [4, 5].
Release into synovial fluid and serum of
cartilage and bone macromolecular fragments
occurs during normal tissue turnover. Changes in
the release pattern, however, are likely to occur as
a result of the OA process. Quantification of such
fragments in body fluids, e.g., synovial fluid and
serum should provide information about the
processes in the joint [6]. There are, however,
confounding factors that influence the levels of
such potential ‘tissue markers’, which needs to be
considered when interpreting results of such
measurements [3, 6]. For instance, serum levels
will depend not only on the release from other
cartilage and bone structures but also on the
elimination rate from the joint cavity as well as in
lymph nodes. Another parameter is the clearance
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from blood which in turn depends on liver
uptake/degradation or possibly kidney filtration
[7]. Serum levels thus represent an integrated
measure reflecting release from all cartilage or
bone structures as well as reflecting elimination at
different steps in the metabolism of fragments.
Another approach to the study of changes in the
tissue, particularly in the synovium and the bone
matrix, is bone scintigraphy which may reflect
pathophysiological changes of these tissues [8]. In
animal models with OA, the isotope uptake is
located to areas of active subchondral bone and in
growing osteophytes [9]. In clinical studies of knee
OA, bone scan abnormalities correlate with
radiographic subchondral sclerosis [10]. Bone
scintigraphy seems to detect OA in the knee joint
(defined as macroscopical changes of the cartilage
on arthroscopy and/or inspection during surgical
intervention) with higher sensitivity and with
better correlation than radiography [11].
Bone scan abnormalities have also been related
to biochemical markers of joint tissue turnover
and one study showed a correlation between the
extent of scintigraphic abnormalities of the knee
joint and osteocalcin in OA in synovial fluid [12].
Since there is a discrepancy between bone scan
abnormalities and radiographic evidence of dis-
ease in OA in the knees as well as the hands, it has
been suggested that the bone scan changes might
more directly reflect the pathological process and
that radiographical abnormalities reflect its struc-
tural sequelae [11, 13].
In a previous study we have quantified serum
concentrations of antigenic fragments of cartilage
oligomeric matrix protein (COMP) and bone
sialoprotein (BSP) in individuals with chronic knee
pain and found increasing concentrations in those
individuals who at the 3-year follow-up showed
radiographic evidence of knee joint OA [4]. COMP
is a non-collagenous protein primarily isolated
from the extracellular matrix of cartilage although
the protein is not unique to this tissue [14]. Thus, it
is found in tendon of bovine [15] and equine origin
[16]. Synovial cells appear to have capacity for
COMP production when stimulated by transform-
ing growth factor b [17]. However, the synovial
capsule of rheumatoid arthritis or OA patients
contains COMP concentrations at least 100-fold
lower than that in cartilage (Saxne et al.,
unpublished observations). Whether human ten-
dons contain COMP has not been shown, but it
appears that the contribution to the circulating
levels from tendon of COMP is low, since serum
concentrations do not change in tendinitis in horse,
albeit levels in tendon decreases [18] . Therefore,
the bulk of circulating COMP most probably
originates from cartilage. BSP has a tissue
restricted distribution and is found in bone only of
the adult individual [19]. Interestingly, using
semiquantitative immunogold technology in low
temperature embedded sections, it has been shown
that BSP is particularly enriched at the bone
interface to cartilage, showing a severalfold higher
concentration compared with other parts of bone
[20, 21]. In an earlier study of patients with
established OA with a mean disease duration at
inclusion of 9 years, COMP levels increased over
the first year in those patients who showed
evidence of progressive joint space narrowing at
the 5-year follow-up [22]. In this study of established
OA, serum levels of COMP were higher in patients
with abnormal bone scans at inclusion than in
those with normal bone scintigraphic findings [22].
In the present study we have examined the
hypothesis that high levels of COMP and BSP in
serum reflect alterations in the tissue turnover in
the knee joints as depicted by bone scan
abnormalities in individuals with chronic knee
pain with or without early signs of radiographic
knee OA.
Method
background
A cohort of individuals with chronic knee pain
(duration q3 months at inclusion) for prospective
follow-up has been recruited by a questionnaire in
a Swedish population. The individuals were aged
35–54 years at recruitment [23].
At the 3 year follow-up, a random sample of 38
individuals were chosen for examination after
excluding those with knee pain due to inflamma-
tory arthritides, major trauma or severe OA (see
below). At the time of the present study the median
age of the 38 individuals was 47 years (range 37–54
years), the median body mass index (BMI) was 26.2
(range 20.3–37.0) and there were 17 females and 21
males. In the initial selection procedure for the
prospective study, individuals with other joint
disorders than OA, those having more severe OA
(Ahlba¨ck grade qI, corresponding to Kellgren and
Lawrence grade 3 or more [23, 24]) and those with
persistent pain due to a major knee trauma were
excluded. All patients reported continuos knee
pain at inclusion.
scintigraphic method
Bone scintigraphy and radiography of both
knees were performed on the same day as the
serum samples were taken.
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An intravenous injection of 370 MBq of tech-
netium-99m labelled methylene diphosphonate was
given. After injection of the radionuclide, an early
phase (perfusion phase) scan was acquired fol-
lowed by a 5 min frame (blood volume phase), both
in anterior projection, using a general purpose
collimator. The late phase (bone uptake) was
acquired after 4 h as 5 min frames in anterior,
lateral and medial projections for both knees using
a high-resolution collimator. The matrix size was
256. The scans were visually evaluated by one
investigator (J.D.) without knowledge of other
patient data. For both the early and the late
phases, the uptake in each knee was classified as
normal (0) or increased using a three point scale
(1 = light, 2 = moderate or 3 = severe). During the
late phase the increased uptake was graded
separately for the patellar, medial or lateral tibial
and femoral compartments, respectively. The
extent of the bone scan abnormalities was
expressed as the sum of the increased localized
uptake score in all compartments during the late
phase.
A random sample of bone scans from
20 individuals (40 knees) were blindly re-read
by another experienced investigator (H.D.) as
well as by the prime investigator (J.D.).
The inter observer variability was low with good
or very good strength of agreement (kappa
0.78–1.00).
radiographic method
All subjects were examined by standing pos-
teroanterior radiographs of both knee joints in
semiflexion with fluoroscopic guidance and with
almost all load on the examined leg. With
fluoroscopic control, the central X-ray beam was
adjusted tangential to the anterior and posterior
aspect of the medial tibial condyle [25]. All
individuals were also examined with a skyline
view of the patellofemoral joints in the standing
position according to Ahlba¨ck [26]. The mini-
mum joint space in the medial and lateral
tibiofemoral compartments and the medial and
lateral compartments of the patellofemoral joint
was measured using a standard mm-ruler. The
margins used for measuring the interbone dis-
tance were chosen according to Buckland-
Wright [25]. Radiographic OA was defined as
joint space narrowing in any of the compart-
ments of the tibiofemoral (Q3.5 mm) and/or
patellofemoral (Q5 mm) joints. The measure-
ments were performed by one examiner (T.B.)
without knowledge of other patient data. The
kappa values for intra- and interobserver agree-
ment of the radiographic readings all exceeded
0.80 [27].
immunoassays
Blood samples were collected in sterile tubes
without additives, allowed to clot for 2 h at room
temperature and centrifuged (1900 g, 10 min).
Serum was stored in aliquots at −80°C. COMP and
BSP were analysed by enzyme-linked immunosor-
bent inhibition assays using polyclonal antisera
[14, 22, 28].The intra-assay variations are Q5% for
COMP and Q10% for BSP. All analyses were made
without knowledge of the results of the other
examinations.
statistical method
Comparisons between groups were performed
using the Mann–Whitney U-test (2-tailed). The
Spearman correlation coefficient was used for
calculating correlations. The chi square test was
used to compare differences in frequencies [29].
P-values Q0.05 were considered significant. Inter-
rater agreement was calculated using kappa
statistics [30].
Results
scintigraphic and radiographic findings
Scintigraphic and radiographic findings refer
to changes in any of the knee joints of each
individual. Six individuals showed abnormalities
Table I.
Raiographic OA
Right TF joint Left TF joint Right PF joint Left PF joint
Scintigraphic Abnormal Normal Abnormal Normal Abnormal Normal Abnormal Normal
Abnormal 6 6 4 5 5 9 5 4
Normal 1 25 3 26 7 17 7 22
P Q 0.05 P Q 0.05 ns ns
The distribution and association of bone scintigraphic and radiographic OA changes of the separate compartments of the knee
joints of individuals with chronic knee pain, N = 38. (TF = tibiofemoral, PF = patellar/patellofemoral).
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in the early phase of bone scintigraphy, five of
these having changes also in the late phase.
Abnormalities in the late phase were detected
in 26/38 individuals, whereof 11 had bilateral
changes. In nine individuals increased radio-
nuclide uptake was seen in the tibiofemoral
compartment, in 11 in the patellar compartment
and in six in both compartments.
Joint space narrowing was found in 23/38
individuals. Of these, six were found in the
tibiofemoral joint, 14 in the patellofemoral joint
Fig. 2. Correlation between serum COMP and the extent
of bone scan abnormalities in the knees of individuals
with knee pain, N = 38. For explanation, see text.
Fig. 1. Serum concentrations of (a) COMP and (b) BSP
in individuals with knee pain with bone scan abnormal-
ities in the knee joints, N = 26 (+) and in individuals with
knee pain without such changes, N = 12 (−). The P-values
denote differences between the groups.
and in three cases changes were found in both
compartments. In 12/23 cases bilateral radio-
graphic changes were found. The association
between the bone phase scintigraphic abnormali-
ties and radiographic OA in the 38 individuals is
shown in Table I. There was a significant
association between scintigraphic and radio-
graphic abnormalities in the tibiofemoral compart-
ments (P Q 0.05), but not in the patellar
compartments.
relationships of markers of matrix turnover
in bone and cartilage and scintigraphic
abnormalities
The serum concentrations of COMP and BSP
were significantly higher in the individuals with
bone scintigraphic abnormalities (P = 0.02 and
P = 0.004, respectively), Fig. 1. Furthermore, the
serum concentrations of COMP, but not BSP,
correlated significantly to the extent of bone
scintigraphic abnormalities for the whole group
(r = 0.56/P = 0.002, r = 0.20/P = 0.23, respectively).
Fig. 2 shows the correlation between serum COMP
and the extent of bone scintigraphic abnormalities.
The correlation between serum COMP and bone
scintigraphy was similar in the groups with
(N = 23) or without (N = 15) radiographic OA-
changes (r = 0.57/P = 0.004, r = 0.56/P = 0.03, re-
spectively).
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Discussion
Quantification in serum of specific tissue-derived
macromolecules or fragments thereof, e.g., COMP
and BSP, offers promise as tools for studying the
pathogenetic mechanisms of tissue damage in both
inflammatory joint diseases such as rheumatoid
arthritis and in OA [6, 22, 31, 32]. In a previous
study we found rising serum levels of both COMP
and BSP in individuals with chronic knee pain
during development of radiographic knee OA
compared to those with normal knee radiographs
[4]. Similar results for COMP were found in a study
of radiographic progression of established knee
OA [22]. In this study, serum COMP levels were
higher in patients with positive bone scans [22].
Interestingly, bone scan changes have also been
shown to predict radiographic progression of knee
OA [33] To investigate if changes in the tissue
turnover as reflected by bone scintigraphy corre-
late with changes in serum levels of COMP and
BSP, these levels were compared with the degree
of bone scintigraphic abnormalities of the knee
joints.
Indeed, we were able to show that individuals
with bone scan abnormalities had significantly
higher serum concentrations of both COMP and
BSP than those with normal bone scans. Further-
more, for serum COMP we found a significant
correlation with the extent of scintigraphic
abnormalities. This suggests that serum concen-
trations of the markers reflect changes in the
turnover in the tissues seen on bone scan. It is
somewhat surprising that serum COMP (derived
from cartilage) but not BSP (derived from bone)
correlates significantly with the extent of bone
scan abnormalities. A possible explanation might
be that changes in cartilage, i.e., COMP, correlate
with global changes in the bone matrix, reflected
by the scintigraphy, whereas serum BSP reflects
more localised changes that are influenced by
other factors. BSP, indeed is particularly enriched
in the narrow zone in the very subchondral bone
[21].
The findings would also be consistent with the
observations by Sharif et al. who found a
correlation between synovial fluid osteocalcin
and bone scan abnormalities, since osteocalcin
is rather evenly distributed in bone [12]. The
findings in our study of serum COMP in relation
to bone scan changes corroborate and extend
the observations in patients with established
OA in another study by Sharif et al., however,
in that study no attempt to relate the COMP
levels to the extent of bone scan changes was made
[22].
The circulating COMP appears to rather
selectively be derived from cartilage tissue
throughout the body, while BSP is derived from
bone. The correlation to the knee joint bone
scintigraphic abnormalities therefore could mean
that the contribution to the circulation from the
knee joints is large enough to show against the
background of circulating molecules. An alterna-
tive explanation could be that OA is a generalised
process and that increased serum levels reflect the
hypermetabolism of many joints [34]. The corre-
lation to bone scan of the knee joints could then
merely reflect that we studied the joints that
presently are symptomatic. Further studies are
needed to solve this question.
The scintigraphic technique focuses on changes
in the turnover of bone. However, we found
changes not only with BSP, derived predominantly
from the subchondral bone, but importantly also of
serum COMP, derived from cartilage. These
findings provide further evidence that the events
coincide in bone and cartilage in the OA
development.
While a number of individuals with scinti-
graphic changes have low levels of COMP and
BSP, in those with normal bone scans, only one
individual had a COMP value above the median for
the bone scan positive group and another a BSP
value above the median of the bone scan positives,
Fig. 1. This suggests that high serum levels
discriminate well between individuals with or
without bone involvement of the knee joints.
In the tibiofemoral joints there was a significant
correlation between radiographic joint space
narrowing and bone scintigraphic abnormalities
which was not the case for the patellofemoral joint
as shown in Table I. Thus, radiography and
scintigraphy in part recognises the same individ-
uals, however, there is a significant proportion,
with bone scan changes without radiographic
abnormalities. This suggests that these individuals
might have ‘preradiographic OA’.
An interesting subgroup is the six subjects with
scan abnormalities in the early phase. Five of them
had late phase scan abnormalities and four had
radiographic changes. The one without bone
uptake could have soft tissue changes. It is
possible that an inflammatory response is present
in these patients with OA.
In conclusion, this study demonstrates that
serum levels of COMP and BSP differ between
groups of individuals with knee pain, that do or do
not show bone scan abnormalities in the knee
joints. The concomitant changes in bone and
cartilage early in disease, focus on the necessity to
take both these compartments into account when
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considering development and intervention of OA.
Furthermore, the findings suggest that measure-
ment of serum levels of these tissue derived
proteins have a potential means for evaluating
changes in cartilage and bone turnover in
individuals with long standing knee pain. This
opens novel possibilities to investigate the early
stages of OA.
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